Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP o |
Oct 2020 |
Bone Marrow Transplantation |
Aplastic Anemia |
A Case Series of Post-Transplantation Cyclophosphamide in Unrelated Donor Hematopoietic Cell Transplantation for Aplastic Anemia |
Jun 2020 |
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Aplastic Anemia |
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients |
Jun 2019 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
A Journey from Blood Cells to Genes and Back |
Aug 2023 |
Annual Review of Genomics and Human Genetics |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes |
Aug 2020 |
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes |
Nov 2020 |
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
Mar 2019 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients |
Nov 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes |
Mar 2019 |
Clin Lymphoma Myeloma Leuk |
Myelodysplastic Syndromes (MDS) |